Vex

Immunohistochemical analysis conditions. (PDF 273 kb

EGFR immunohistochemistry and <i>EGFR</i> silver in situ hybridization analysis in colorectal cancer.

<p>EGFR IHC shows heterogeneous staining with intensive membranous reactivity in the middle (<b>a)</b>. <i>EGFR</i> SISH from the intensively stained area showing gene clusters (<b>b</b>). <i>EGFR</i> SISH from the surrounding areas with weak or negative EGFR IHC staining shows marginally elevated or normal gene copy numbers (<b>c–d</b>).</p

Characteristics of anti-EGFR treated <i>KRAS</i> wild type metastatic colorectal cancer patients.

<p>CAP, capecitabine; EGFR = epidermal growth factor receptor; IRI, irinotecan; OXA, oxaliplatin.</p><p>Original discovery patient cohort (<b>a</b>). Independent validation patient cohort (<b>b</b>). Combined chemorefractory patient cohort (<b>c</b>).</p

Progression-free survival and overall survival of anti-EGFR treated patients according to EGFR gene copy number.

<p>The hazard ratios and confidence intervals of the original discovery, validation, and combined chemorefractory patient cohorts are shown. A high <i>EGFR</i> GCN (IHC guided SISH) is associated with an improved disease outcome in all three <i>KRAS</i> wild type metastatic colorectal cancer patient cohorts treated with anti-EGFR therapy (two independent cohorts and one combined cohort of chemorefractory patients).</p

Additional file 6: of Human breast cancer cells educate macrophages toward the M2 activation status

Representative flow cytometry dot plot of IL-4 macrophages A human macrophages in the presence of IL-4 with or without breast cancer cell line conditioned media (CM), detected with antibodies against CD14, CD16, CD163, CD200R and CD86 B mean fluorescence intensity (MFI) of the analyzed surface-markers. (PDF 2715 kb